Asset Allocation

As of February 28, 2026.
Type % Net
Cash 1.34%
Stock 23.88%
Bond 71.66%
Convertible 0.00%
Preferred 2.45%
Other 0.67%
View Asset Allocation
Start Trial

Market Capitalization

Large --
Mid --
Small --
No Data Available
View Market Capitalization
Start Trial

Region Exposure

% Developed Markets: 98.59%    % Emerging Markets: 0.37%    % Unidentified Markets: 1.04%

Americas 93.99%
93.78%
Canada 85.07%
United States 8.71%
0.21%
As of February 28, 2026. Region breakdown data is calculated by using the long position holdings of the portfolio.
Greater Europe 4.62%
United Kingdom 1.88%
2.59%
Denmark 0.00%
France 0.86%
Germany 0.01%
Ireland 0.27%
Italy 0.36%
Netherlands 0.17%
Sweden 0.90%
Switzerland 0.02%
0.14%
Poland 0.14%
0.01%
Israel 0.01%
Greater Asia 0.35%
Japan 0.33%
0.02%
Australia 0.02%
0.00%
0.00%
Unidentified Region 1.04%

Bond Credit Quality Exposure

AAA 29.95%
AA 12.62%
A 34.80%
BBB 15.01%
BB 0.00%
B 0.00%
Below B 0.00%
    CCC 0.00%
    CC 0.00%
    C 0.00%
    DDD 0.00%
    DD 0.00%
    D 0.00%
Not Rated 1.28%
Not Available 6.34%
Short Term 0.00%
As of February 28, 2026
View Bond Credit Quality Exposure
Start Trial

Stock Sector Exposure

Cyclical
13.28%
Materials
0.32%
Consumer Discretionary
3.93%
Financials
7.08%
Real Estate
1.94%
Sensitive
9.22%
Communication Services
1.12%
Energy
0.00%
Industrials
4.56%
Information Technology
3.54%
Defensive
3.14%
Consumer Staples
1.94%
Health Care
0.55%
Utilities
0.64%
Not Classified
74.37%
Non Classified Equity
0.32%
Not Classified - Non Equity
74.04%
As of February 28, 2026
View Region Exposure
Start Trial

Bond Sector Exposure

As of February 28, 2026
Type % Net
Government 15.64%
Corporate 45.57%
Securitized 1.60%
Municipal 26.27%
Other 10.93%
View Bond Sector Exposure
Start Trial

Bond Maturity Exposure

Short Term
0.15%
Less than 1 Year
0.15%
Intermediate
61.16%
1 to 3 Years
15.66%
3 to 5 Years
9.56%
5 to 10 Years
35.93%
Long Term
34.42%
10 to 20 Years
17.61%
20 to 30 Years
13.29%
Over 30 Years
3.52%
Other
4.27%
As of February 28, 2026
View Bond Maturity Exposure
Start Trial